logo-loader
viewAvacta Group PLC

Avacta Group heading into 'crucial year' for its cancer therapeutics programmes

Proactive Research analyst Ed Stacey says Avacta (LON:AVCT) is preparing for a crucial year in its cancer therapeutics programmes in 2020, with an opportunity now identified for a targeted chemotherapy programme to enter clinical trials during the first half.

Stacey says alongside the recent release of their interim results, Avacta's announced a proposed equity placing of up to £9mln.

The biggest deployment of the new funds will be the AVA6000 pro-doxorubicin tumour-targeted chemotherapy programme developed via the Tufts collaboration.

Quick facts: Avacta Group PLC

Price: 25.3 GBX

AIM:AVCT
Market: AIM
Market Cap: £44.54 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Symphony Environmental Technologies has game changing...

Symphony Environmental Technologies PLC (AIM: SYM) CEO Michael Laurier joined Steve Darling from Proactive with news the company has received U.S. Food & Drugs Administration approval or its d2p antimicrobial technology. Laurier discusses what that means for the company and what their...

15 hours, 14 minutes ago

2 min read